834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial von Chabria, Shiven, De Wit, Stephane, Pierce, Amy, Shepherd, Bronagh M, Warwick-Sanders, Michael, Du, Fangfang, Wang, Marcia, Clark, Andrew, Ackerman, Peter

Volltext

Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study von Llibre, Josep M, Aberg, Judith A, Walmsley, Sharon, Velez, Juan, Zala, Carlos, Crabtree Ramírez, Brenda, Shepherd, Bronagh, Shah, Rimi, Clark, Andrew, Tenorio, Allan R, Pierce, Amy, Du, Fangfang, Li, Bo, Wang, Marcia, Chabria, Shiven, Warwick-Sanders, Michael

Volltext

Physical rehabilitation interventions for adult patients with critical illness across the continuum of recovery: an overview of systematic reviews protocol von Connolly, Bronwen, O'Neill, Brenda, Salisbury, Lisa, McDowell, Kathryn, Blackwood, Bronagh

Volltext